Radha Madhav Corporation has reported zero operational revenue for FY26 as the company navigates its NCLT-approved revival process. While leadership changes were announced, trading in the company’s securities remains suspended on BSE and NSE due to outstanding listing fee issues, despite recent penalty payments.
Radha Madhav Corporation FY26 Financial and Operational Update
Revenue from operations stood at Rs 0.00 million for FY26; Net loss reported at Rs 4.04 million.
Reader Takeaway: The company faces zero operational activity and ongoing trading suspension despite paying significant exchange penalties.
What just happened
Radha Madhav Corporation has released its financial performance for FY26, reporting zero revenue from operations. Total income was restricted to Rs 15.23 million, derived entirely from other sources, resulting in a net loss of Rs 4.04 million for the year. This marks a sharp decline from the Rs 1.40 million operational revenue reported in the previous fiscal year.
Why this matters
The company is currently undergoing a revival process under an NCLT-approved resolution plan. The lack of operational revenue highlights the significant hurdles in restarting its core business activities. Additionally, the company's securities remain suspended on both the BSE and NSE due to procedural delays in listing fee payments, despite the company settling over Rs 1.27 crore in penalties with each exchange as of June 2026.
The backstory
Following an NCLT order dated August 1, 2022, the company initiated a share capital restructuring. Although a temporary ISIN (INE172H01022) has been issued, the firm is still waiting for the final listing approval required to resume trading. Furthermore, the proposed acquisition of Phytoatomy Private Limited—announced in November 2023—remains incomplete, with no change in control or ownership reported.
What changes now
Management has appointed Nitin Jain as Whole-time Director and CFO, alongside Vijay Patel as Whole-time Director, for a three-year term effective August 31, 2026. The company has also retained M/s. Ajay Shobha & Co. as Statutory Auditor through 2028.
Risks to watch
Investors should note the persistent trading suspension and the uncertainty surrounding the Phytoatomy acquisition. The company’s ability to generate operational cash flow remains the most significant risk to its long-term viability under the revival plan.